glp 1 study Discover How GLP-1 Trials Are Not One-Size-Fit-All Clinical efficacy results from clinical

Note: animal studies indicate that high doses of DPP-4 inhibitors & GLP-1 agonists cause expansion of cells of the pancreatic ductal glands and can cause premalignant pancreatic intraepithelial lesions (PanIN) that have the potential to progress to pancreatic adenocarcinoma

And if GLP-1 isnt a familiar term, youve probably heard of one of the medications in this drug class, such as Ozempic or Wegovy

It is projected to reach USD 1,062.90 billion by 2035

And a quick note on safety: if you're immunocompromised, have a central line, or have significant chronic illness, discuss probiotics with your clinician first

Set Points approach includes combining medication with personalized lifestyle changes such as nutrition and exercise plans to optimize results

DPP-4 inhibitors are generally well tolerated, with a low risk of contributing to hypoglycemia when used as monotherapy or in combination with metformin due to their glucose-dependent mechanism of action